Antibody Discovery Market Growth Forecast to 2032 The Antibody Discovery Market is entering a transformative phase driven by next-generation screening platforms and precision engineering. Rapid innovation in AI-enabled screening and single-cell analysis is reshaping industry size and industry share dynamics. Business growth is underpinned by deep market research and actionable market insights that spotlight high-value market segments and evolving market opportunities. Market Size and Overview The Global Antibody Discovery Market size is estimated to be valued at USD 3.15 Bn in 2025 and is expected to reach USD 7.18 Bn by 2032, exhibiting a compound annual growth rate (CAGR) of 12.0% from 2025 to 2032. This comprehensive Antibody Discovery Market report offers insights into market growth strategies and market revenue projections across key market segments. Shifts in bioprocessing pricing are expected to drive market revenue streams across multiple sectors, while complex regulatory pathways act as significant market restraints. The Antibody Discovery Market size trajectory aligns with evolving market drivers such as AI-driven screening and single B-cell technologies and underscores emerging market opportunities amid tightening compliance costs. Use Case Scenarios • In 2024, WuXi Biologics deployed an AI-enabled antibody screening platform for oncology targets, reducing lead time by 40% and helping clients capture greater market share while surfacing new market opportunities. • Genmab’s 2025 collaboration with a top biopharma delivered a bispecific antibody for autoimmune disorders, demonstrating 30% improved binding affinity and validating scalable integration that meets stringent market challenges. • Harbour BioMed applied single-cell sequencing workflows in 2024 for neurodegenerative antigen discovery, streamlining candidate selection and driving a 25% boost in operational efficiency amid competitive market dynamics. Policy and Regulatory Impact • In 2024, the FDA’s updated accelerated approval guidance for antibody therapeutics shortened review timelines by 25%, expanding the market scope for novel mAb candidates and fueling industry growth in the U.S. • The EMA revised biotech evaluation guidelines in early 2025 to standardize bispecific antibody assessments, addressing international quality standards and alleviating market restraints tied to divergent regulations. • China’s NMPA launched a priority review pathway in late 2024 for innovative biologics, reinforcing market dynamics in Asia-Pacific by incentivizing local R&D investments and mitigating compliance costs. Key Players • WuXi Biologics • GenScript • Genmab • Harbour BioMed • ImmunoPrecise • AbbVie • Amgen • Sanofi • Roche • AstraZeneca • BioNTech • Pfizer • Eli Lilly • Novartis • Johnson & Johnson • Regeneron • Merck • Bristol Myers Squibb ‣ Antibody Discovery Market: https://www.coherentmi.com/industry-reports/antibody-discovery-market